Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 28, 2010; 16(32): 4095-4099
Published online Aug 28, 2010. doi: 10.3748/wjg.v16.i32.4095
Published online Aug 28, 2010. doi: 10.3748/wjg.v16.i32.4095
Table 2 Efficacy and safety at week 52 n (%)
| Variables | High baseline ALT group | Controls | P value |
| Decrease in HBV DNA level (log10 copies/mL) | 7.03 | 6.17 | < 0.05 |
| HBV DNA negative rate | 29/40 (72.5) | 24/40 (60) | < 0.05 |
| ALT normalization rate | 30/40 (75.0) | 31/40 (77.5) | > 0.05 |
| HBeAg negative rate | 18/40 (45.0) | 11/40 (27.5) | < 0.05 |
| HBeAg seroconversion rate | 15/40 (37.5) | 9/40 (22.5) | < 0.05 |
| HBsAg negative rate | 4/40 (10.0) | 1/40 (2.5) | < 0.05 |
| HBsAg seroconversion rate | 3/40 (7.5) | 0 | < 0.05 |
| Viral breakthrough | 2/40 (5.7) | 3/40 (7.5) | > 0.05 |
| Viral resistance | 1/40 (2.9) | 2/40 (5) | > 0.05 |
| Increased blood creatine kinase | 5/40 (12.5) | 4/40 (10) | > 0.05 |
- Citation: Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol 2010; 16(32): 4095-4099
- URL: https://www.wjgnet.com/1007-9327/full/v16/i32/4095.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i32.4095